Systemic lupus erythematosus and the SLE galaxy

Autoimmunity Reviews

Volumn 10, Issue 1, 2010, Pages 1-2

  Meroni, P L ^a   Shoenfeld, Y ^b  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ARTERY THROMBOSIS; COGNITIVE DEFECT; EDITORIAL; EPILEPSY; HYPERTENSION; KIDNEY FAILURE; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 78149357936     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.09.006     Document Type: Editorial

References (15)

1. Smith P.P., Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev 2010, 10(1):43-45. (this issue).
2. Doria A., Zen M., Canova M., Bettio S., Bassi N., Nalotto L., et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010, 10(1):55-60. (this issue).
3. Tincani A., Andreoli L., Chighizola C., Meroni P.L. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 2009, 42(4):257-259.
4. Gigante A., Gasperini M.L., Cianci R., Barbano B., Giannakakis K., Di Donato D., et al. Antiphospholipid antibodies and renal involvement. Am J Nephrol 2009, 30(5):405-412.
5. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007 Apr, 36(5):297-315.
6. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, 10(1):46-50. (this issue).
7. Andreoli L., Bazzani C., Taraborelli M., Reggia R., Lojacono A., Brucato A., et al. Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. Autoimmun Rev 2010, 10(1):51-54. (this issue).
8. Gualtierotti R., Biggioggero M., Meroni P.L. Pathogenesis of systemic lupus erythematosus. Autoimmun Rev 2010, 10(1):3-7. (this issue).
9. Baudino L., Yoshinobu K., Morito N., Santiago-Raber M.L., Izui S. Role of endogenous retroviruses in murine SLE. Autoimmun Rev 2010, 10(1):27-34. (this issue).
10. Muñoz L.E., Janko C., Schulze C., Schorn C., Sarter K., Herrmann M. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 2010, 10(1):8-17. (this issue).
11. Pisetsky D.S., Ullal A.J. The blood nucleome in the pathogenesis of SLE. Autoimmun Rev 2010, 10(1):35-37. (this issue).
12. Torres-Aguilar H., Blank M., Jara L.J., Shoenfeld Y. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010, 10(1):8-17. (this issue).
13. La Cava A. Modulation of autoimmunity with artificial peptides. Autoimmun Rev 2010, 10(1):18-21. (this issue).
14. Mozes E., Sharabi A. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus. Autoimmun Rev 2010, 10(1):22-26. (this issue).
15. Conti F., Perricone C., Ceccarelli F., Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 2010, 9(11):716-720.